Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD)

NCT05835414 | Unknown Phase 2 DMC FDA Device

• 1 other identifier: BEP-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans. The main questions the study aims to answer are:

• Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD?
• Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD?
• Does health-related quality of life improve among veterans after 30 sessions of eTMS as an adjunct to standard-of-care therapies for chronic TSRD? Participants will undergo 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD, weekly reassessment during treatment, and intermittent follow-up for 36 weeks post-enrollment.

Conditions

Trauma and Stressor Related Disorders

Keywords

Transcranial Magnetic Stimulation; Chronic Trauma and Stressor Related Disorders; Veterans RAND 36-item health survey (VR-36); Health Related Quality of Life; EEG; Alpha Rhythms

Outcome Measures

Primary Outcomes (2)

• Number of participants with device-related serious adverse events

  To address safety of the procedure, the study investigators will report number of participants (of 30 initial cohort) with expected, device-related serious adverse events (SAE's) or unexpected, device-related SAE's during treatment

  6 weeks

• Rate of participants completing 80% of scheduled visits

  To assess feasibility of the procedure, the study investigators will report the rate of participants (for initial cohort of 30) completing \>= 80% of the 30 scheduled eTMS sessions

  6 weeks

Secondary Outcomes (1)

• Mean change in Veterans RAND 36-item health survey (VR-36) mental component scores (MCS)

  6 weeks

Study Arms (1)

Adjunctive eTMS treatment (no delay)

EXPERIMENTAL

6 weeks (30 sessions) of daily eTMS as an adjunct to standard of care TSRD treatment

Device: Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)

Interventions

Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS) DEVICE

Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.

Adjunctive eTMS treatment (no delay)

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Positive identification as a Veteran per discharge paperwork (DD-214, DD-215, NGB-22, NGB-22A) and photo ID, or Veterans Health Administration Veteran Health Identification Card (VHIC)
• Presence of deployment-related stressful events (as defined by the Deployment Risk \& Resilience Inventory-2, DRRI-2)
• Trauma event(s) (defined on the Life Experiences Checklist for DSM-5, LEC-5)
• Presence of 6 months or more of 6 or more "moderate" or worse symptoms from any of the five categories associated with stress disorders as operationalized on the PTSD Checklist for DSM-5 (PCL-5; intrusion, altered mood and cognitions, dissociation, avoidance, and arousal).
• Informed consent for study participation, off label-eTMS, and data use
• Enrollment in addiction services, if meets standard addiction treatment criteria
• Enrollment in opioid reduction services, if dependent on opioids and morphine equivalent daily dose exceeds 50 mg (50 morphine equivalent daily dose, MEDD)
• Agreement to limit daily alcoholic beverage consumption to no more than 2 servings
• Signed pain contract, if MEDD \>= 80, per State of Ohio prescribing guidelines

You may not qualify if:

• Uncontrolled medical, psychological or neurological conditions including, but not limited to:
• Uncontrolled psychosis or mania
• Uncontrolled seizure disorder or EEG abnormalities that indicate risk of seizure, i.e., epileptiform discharges during the EEG recording
• Uncontrolled cardiac, pulmonary, or endocrine disorder (e.g., diabetes)
• Acute pain or illness
• Active, untreated addiction to prescription drugs, alcohol or illicit substances (not including cannabis or derivatives, which are available in many states under medical prescription or for recreational use)
• Clinically significant medical condition or abnormality that in the Investigator's judgment might pose a potential safety risk to the subject or limit the interpretation of the trial results
• Pregnant, or female unwilling to use effective birth control during the course of the trial (unless cleared for participation by obstetrician/gynecologist)
• Absolute contraindications to TMS: Presence of aneurysm clips or coils, cochlear or ocular implant, cortical epidural stimulator, deep brain stimulator, pacemaker or defibrillator, retained intracranial metal foreign body (bullets, shrapnel - excluding titanium and oral implants), steel stents or shunts, active vagal nerve stimulator, ventriculoperitoneal (VP) shunt.
• Prior TMS treatment
• Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures

Sponsors & Collaborators

• Marcia Bockbrader, MD PhD: lead

Study Sites (1)

BEP Medical Group LLC

Columbus, Ohio, 43221, United States

RECRUITING

MeSH Terms

Conditions

Trauma and Stressor Related Disorders

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Mental Disorders

Intervention Hierarchy (Ancestors)

Magnetic Field Therapy; Therapeutics

Central Study Contacts

Marcia A Bockbrader, MD, PhD

CONTACT

614-670-4000; dr.marcie@bepmedicalgroup.com

Neil B Austin

CONTACT

614-670-4000; neil@bepmedicalgroup.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator
• Expanded Access: Yes

Model Details: This will be a staged, open-label, Phase II/III safety, feasibility, and efficacy investigational device trial. A staged approach will be utilized to assess safety, feasibility, and preliminary efficacy with 30 participants with an interim analysis after data collection at 6 weeks. If safety benchmarks are passed, the study will proceed with Stage 2, in which an additional 270 participants will be enrolled using randomization to multiple baselines for efficacy analyses.

Study Record Dates

• First Submitted: April 18, 2023
• First Posted: April 28, 2023
• Study Start: April 10, 2023
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2025
• Last Updated: May 6, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)